INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 49m ago
HOUSE PTR8m ago
SEC 13F8m ago
ROBINHOOD CHAIN8m ago
SEC FORM 4/Grant or awardVerified data

Douglass Brian Robb reported RGEN

CHIEF PRODUCT OFFICER · REPLIGEN CORP · REPLIGEN CORP — Stock Option (Right to Buy)

Side
A
Value
—
Shares
675
Price
—
Executed
Oct 6, 2026
Disclosed
Oct 8, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Oct 6 executedOct 8, 2026 disclosed

RGEN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · RGEN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    13
    DR
    Douglass Brian RobbCHIEF PRODUCT OFFICER
    RGENREPLIGEN CORP
    Grant or award
    		A—
    700 sh
    		Oct 6, 2026Oct 8, 2026
    traded Oct 6, 2026
    		+2dSEC FORM 4

    Evidence

    12
    GK
    Garland Jason KCFO
    RGENREPLIGEN CORP
    Tax withholding
    		F$80K
    421 sh
    		Sep 25, 2026Sep 28, 2026
    traded Sep 25, 2026
    		+3dSEC FORM 4

    Evidence

    12
    LO
    Loeillot OlivierDirector, Chief Executive Officer
    RGENREPLIGEN CORP
    Option exercise · 10b5-1 plan
    		M$1.30M
    8,404 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    18
    LO
    Loeillot OlivierDirector, Chief Executive Officer
    RGENREPLIGEN CORP
    Open-market sale · 10b5-1 plan
    		SELL$1.60M
    8,404 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    9
    LO
    Loeillot OlivierDirector, Chief Executive Officer
    RGENREPLIGEN CORP
    Option exercise · 10b5-1 plan
    		M$706K
    4,542 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    15
    LO
    Loeillot OlivierDirector, Chief Executive Officer
    RGENREPLIGEN CORP
    Open-market sale · 10b5-1 plan
    		SELL$863K
    4,542 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    11
    LO
    Loeillot OlivierDirector, Chief Executive Officer
    RGENREPLIGEN CORP
    Option exercise · 10b5-1 plan
    		M—
    4,542 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    11
    LO
    Loeillot OlivierDirector, Chief Executive Officer
    RGENREPLIGEN CORP
    Option exercise · 10b5-1 plan
    		M—
    8,404 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-065462
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 6, 2026
    Published
    Oct 8, 2026
    Ingested by INSIDER
    Nov 5, 02:12 UTC
    Last re-read
    Nov 5, 02:12 UTC

    Extracted facts

    Filer
    Douglass Brian Robb
    Role
    CHIEF PRODUCT OFFICER
    Transaction
    Grant or awardAs filed: “A”
    Asset
    REPLIGEN CORP — Stock Option (Right to Buy)
    Ticker
    RGEN
    Shares
    675
    Price per share
    $0
    Execution date (reported)
    Oct 6, 2026
    Owned after transaction
    675 shares
    Days from execution to publication
    2

    What this establishes

    Douglass Brian Robb filed this Form 4 reporting a grant or award of RGEN on Oct 6, 2026. It became public on Oct 8, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    CHIEF PRODUCT OFFICER
    Douglass Brian Robbcik:0002104618
    Issuer
    REPLIGEN CORPcik:0000730272

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.